StockNews.AI
LEXX
StockNews.AI
216 days

Lexaria's Human GLP-1 Study #5 Receives Independent Review Board Approval

1. Positive animal study supports human trial for oral DehydraTECH-liraglutide. 2. Ethics board approval received; trial compares oral vs. injected liraglutide.

2m saved
Insight
Article

FAQ

Why Bullish?

Successful trials can enhance LEXX's market positioning, similar to past FDA approvals boosting stock prices.

How important is it?

The article's focus on clinical study approvals is crucial for LEXX's future product development.

Why Long Term?

Long-term growth anticipated as DehydraTECH-liraglutide enters the market, fostering investor confidence.

Related Companies

LEXXSAXA
Positive results in a recent animal study strongly supports first-ever human investigation for DehydraTECH-liraglutide in an oral capsule format KELOWNA, BC / ACCESSWIRE / January 15, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce that it has received the necessary independent ethics board approval required for its contract research organization ("CRO") to begin to implement and execute human pilot study GLP-1-H25-5 (the "Study"). The Study will compare an oral version of liraglutide, formulated from the DehydraTECH-processing of Saxenda® ("DehydraTECH-liraglutide") to the conventional injected liraglutide (Saxenda®).

Related News